1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
BioVie Inc.

BioVie Inc.

BIVIW
BioVie Inc.US flagNASDAQ
0.30
USD
- -
- -
2.52MMarket Cap
BioVie Inc.
BIVIW
(NASDAQ)

Recent

price

0.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
70.46
24.57
-7.76
274.8
157.37
14.11
52.5
-413.09
22.61
14.69
42.11
25.05
9.93
1.36
1.36
Book Value per Share
70.46
24.57
-7.76
-96.46
-163.41
-256.15
5.68
-445.2
16.16
9.84
39.41
23.83
9.66
1.32
1.32
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
-1
-2
-2
-17
-130
-26
-50
-32
-18
-22
-22
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-1
-1
-1
- -
-23
4
15
20
15
18
10
10
Working Capital
- -
- -
- -
- -
1
1
- -
- -
- -
12
5
- -
- -
- -
- -
LT Debt
- -
- -
- -
2
1
- -
2
-21
5
4
15
16
19
10
10
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-97.24
- -
- -
-86.6
-380.46
-218.03
- -
- -
-598.18
-528.7
-208.26
-101.64
-150.76
-150.76
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
8
8
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
Total Current Assets
22
17
14
Cash, Cash Equivalents & STI
21
13
9
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
3
2
4
Payables & Accruals
3
2
4
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
72.22%
53.66%
-45.98%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
151.11%
-8.59%
25.83%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Lexicon Pharmaceuticals, Inc. (LXRX)
Oxurion N.V. (OXUR.BR)
Replimune Group, Inc. (REPL)
Cerevel Therapeutics Holdings, Inc. (CERE)
Caladrius Biosciences, Inc. (CLBS)
Appili Therapeutics Inc (APLIF)
Business
BioVie Inc. is a clinical-stage biopharmaceutical company that develops drug therapies for neurological and neurodegenerative disorders and advanced liver disease. Founded in 2013 and headquartered in Carson City, Nevada, the company focuses on bezisterim (NE3107), an investigational oral small molecule being studied for Alzheimer’s disease, Parkinson’s disease and Long COVID; and BIV201, a continuous-infusion terlipressin formulation being developed for complications of advanced liver cirrhosis, including ascites. BioVie’s product and development portfolio includes neuroscience and hepatology programs, with bezisterim designed to reduce inflammation and improve insulin sensitivity while BIV201 is delivered via a small portable pump for home use. In 2026, the company reported topline results from its Phase 2 SUNRISE-PD trial in early Parkinson’s disease; completed the treatment phase and later reported topline results from its Phase 2 ADDRESS-LC trial in Long COVID; and updated its Parkinson’s Phase 3 development program after corresponding with the FDA on Phase 3 trial design. The Long COVID program was fully funded by a U.S. Department of War grant, and the company also hosted investor webcasts to discuss both the Parkinson’s and Long COVID data readouts. BioVie operates in the United States and advances its programs through clinical trials and regulatory engagement, with its lead assets positioned for potential expansion into additional indications within neurology and liver disease.